» Articles » PMID: 15694934

Nicotine Induces Mitogen-activated Protein Kinase Dependent Vascular Smooth Muscle Cell Migration

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2005 Feb 8
PMID 15694934
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Cigarette smoke, specifically the nicotine contained within, has been shown to cause ultrastructural changes in vascular endothelium resulting in the development of atherosclerosis. Our study examines the effects of nicotine on vascular smooth muscle cell (VSMC) migration and attempts to eludicidate the cellular mechanisms governing those effects. Bovine aortic VSMC were cultured in 10% fetal bovine serum (FBS) growth media and exposed to 10(-8) nicotine for varying periods of time. Boyden chamber chemotaxis assays and a scrape injury model using confluent cells were used to assess cell motility. Activation of the mitogen-activated protein kinases (MAPK), p38 and p44/42, was assessed using Western blotting methods. Nicotine, itself, did not cause significant VSMC migration. However, augmented migration was seen in nicotine-treated VSMCs (16.6+/-3-fold) and media (17.0+/-4-fold) with 10% FBS as chemoattractant. Inhibitors of p38 and p44/42 diminished this migration by 48.5+/-6% and 29.4+/-2%, respectively. Immunoblotting verified p38 and p44/42 activation with nicotine and inhibition with inhibitors of p38 and p44/42. Nicotine-treated endothelial cell (EC) conditioned media (CM) was shown to increase migration 20.3+/-l.l-fold. This chemotactic effect was diminished both with heat treatment and serial dilution. In conclusion, nicotine enhances the chemoatactiveness of VSMC. This migration is mediated via the MAPKs p38 and p44/42. Nicotine causes EC production of a chemoattractant molecule that enhances VSMC migration.

Citing Articles

Addressing Cardiovascular Toxicity Risk of Electronic Nicotine Delivery Systems in the Twenty-First Century: "What Are the Tools Needed for the Job?" and "Do We Have Them?".

Chandy M, Hill 3rd T, Jimenez-Tellez N, Wu J, Sarles S, Hensel E Cardiovasc Toxicol. 2024; 24(5):435-471.

PMID: 38555547 PMC: 11485265. DOI: 10.1007/s12012-024-09850-9.


The controversial effect of smoking and nicotine in SARS-CoV-2 infection.

Salehi Z, Nobakht Motlagh Ghoochani B, Hasani Nourian Y, Azimzadeh Jamalkandi S, Ghanei M Allergy Asthma Clin Immunol. 2023; 19(1):49.

PMID: 37264452 PMC: 10234254. DOI: 10.1186/s13223-023-00797-0.


An integral perspective of canonical cigarette and e-cigarette-related cardiovascular toxicity based on the adverse outcome pathway framework.

Ding R, Ren X, Sun Q, Sun Z, Duan J J Adv Res. 2022; 48:227-257.

PMID: 35998874 PMC: 10248804. DOI: 10.1016/j.jare.2022.08.012.


Nicotine has no significant cytoprotective activity against SARS-CoV-2 infection.

Zheng F, Lian E, Ramirez G, McAlister C, Zhou S, Zhang W PLoS One. 2022; 17(8):e0272941.

PMID: 35980910 PMC: 9387791. DOI: 10.1371/journal.pone.0272941.


Nicotine and vascular dysfunction.

Whitehead A, Erwin A, Yue X Acta Physiol (Oxf). 2021; 231(4):e13631.

PMID: 33595878 PMC: 8026694. DOI: 10.1111/apha.13631.